Biogen (NASDAQ:BIIB) Releases Earnings Results

Biogen (NASDAQ:BIIB) issued its earnings results on Wednesday. The biotechnology company reported $3.44 earnings per share for the quarter, beating analysts’ consensus estimates of $3.43 by $0.01, Zacks reports. Biogen had a return on equity of 14.98% and a net margin of 16.81%. Biogen updated its FY 2025 guidance to 15.250-16.250 EPS.

Biogen Stock Performance

NASDAQ:BIIB opened at $138.45 on Friday. The company’s 50-day moving average price is $147.73 and its 200-day moving average price is $174.05. The company has a current ratio of 1.26, a quick ratio of 0.80 and a debt-to-equity ratio of 0.28. The company has a market cap of $20.17 billion, a P/E ratio of 12.51, a P/E/G ratio of 1.65 and a beta of -0.08. Biogen has a twelve month low of $128.51 and a twelve month high of $238.00.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BIIB shares. The Goldman Sachs Group lowered their price objective on Biogen from $281.00 to $245.00 and set a “buy” rating for the company in a research report on Thursday. Morgan Stanley cut their target price on Biogen from $192.00 to $157.00 and set an “equal weight” rating on the stock in a research note on Thursday. Sanford C. Bernstein began coverage on Biogen in a research note on Tuesday. They issued a “market perform” rating and a $160.00 price objective on the stock. Needham & Company LLC reiterated a “hold” rating on shares of Biogen in a research note on Thursday. Finally, Wells Fargo & Company lowered their target price on shares of Biogen from $165.00 to $140.00 and set an “equal weight” rating on the stock in a report on Thursday. Seventeen research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $211.96.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.